Journal of Drugs in Dermatology (JDD) released a clinical study highlighting the efficacy of Triple Protection Factor Broad Spectrum Sunscreen, TPF 50, to prevent skin sun damage and non-melanoma skin cancer (NMSC). In this head-to-head comparison study, investigators Enzo Emanuele MD, PhD, James M. Spencer MD, MS and Martin Braun MD found that TPF50 was more effective than both the main DNA repair and AO existing products.
Continued exposure to ultraviolet radiation (UVR) is one of the major risk factors for photo-aging and the development of NMSC. Mainstream sunscreens cannot ensure a complete protection against all molecular lesions associated with UVR exposure, making the emergence of TPF 50 a significant advance in preventive science.
"JDD offers one of the fastest routes for disseminating dermatologic information. The JDD is pleased to publish this relevant, timely breakthrough research for dermatologists. This new information is important, very beneficial and is another treatment in the dermatologist's armamentarium in preventing skin cancers," said Robins, editor-in-chief and professor emeritus of Dermatology at New York University School of Medicine.
The study entitled, An Experimental Double-Blind Irradiation Study of a Novel Topical Product (TPF 50) Compared to Other Topical Products With DNA Repair Enzymes, Antioxidants, and Growth Factors With Sunscreens: Implications for Preventing Skin Aging and Cancer, is featured in the March issue of JDD, Volume 13, Issue 3—Special Topics at AAD—with expanded distribution at the American Academy of Dermatology annual conference on March 21, 2014 in Denver, Colorado. You may access the article here.